Current Report Filing (8-k)
May 01 2018 - 8:47AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): April 30, 2018
CANCER
GENETICS, INC.
(Exact
Name of Registrant as Specified in its Charter)
Delaware
|
|
001-35817
|
|
04-3462475
|
(State
or Other
|
|
(Commission
|
|
(IRS
Employer
|
Jurisdiction
of
Incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
201
Route 17 North 2nd Floor, Rutherford, New Jersey 07070
(Address of Principal Executive Offices) (Zip Code)
Registrant’s
telephone number, including area code
(201) 528-9200
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined by Rule 405 of the Securities Act of 1933 (17 §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
On
April 30, 2018, the Board of Directors of Cancer Genetics, Inc. (“Cancer Genetics” or the “Company”) appointed
John A. Roberts as the Company’s Chief Executive Officer and President. Mr. Roberts had been serving as the Company’s
Chief Executive Officer on an interim basis since February 2, 2018 in addition to his role as our Chief Operating Officer and
Executive Vice President, Finance, a position he has held since he joined the Company in July 2016.
Prior
to joining Cancer Genetics, from August 1, 2015 to June 30, 2016, Mr. Roberts served as the Chief Financial Officer for VirMedica,
Inc., an innovative technology solutions company that provides an end-to-end platform that enables specialty drug manufacturers
and pharmacies to optimize product commercialization and management. Prior to VirMedica, from August 1, 2011 to July 31, 2015,
Mr. Roberts was the Chief Financial and Administrative Officer for AdvantEdge Healthcare Solutions, a global healthcare analytics
and services organization. Prior to that, Mr. Roberts was the Chief Financial Officer and Treasurer for InfoLogix, Inc., a publicly-traded
healthcare-centric mobile software and solutions provider. He has also held CFO roles at leading public medical device and healthcare
services firms including Clarient, Inc., a publicly-traded provider of diagnostic laboratory services and Daou Systems, Inc.,
a publicly-traded healthcare IT software development and services firm. In addition, he has held key senior executive roles with
MEDecision, Inc., HealthOnline, Inc. and the Center for Health Information. Mr. Roberts earned a Bachelor of Science and a Master’s
degree in Business Administration from the University of Maine. He is Chairman of the Board of Directors for the Drug Information
Association (DIA), a global neutral forum enabling drug developers and regulators access to insights and collaboration.
Mr.
Roberts will continue to be compensated pursuant to the terms of his employment agreement dated as of July 11, 2016, subject to
further review by the compensation committee of the board. The description of his employment agreement is set forth in the Company’s
definitive proxy statement filed on April 21, 2017 and incorporated herein by reference.
There
are no transactions between Mr. Roberts and the Company that would be reportable under Item 404(a) of Regulation S-K.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
CANCER
GENETICS, INC.
|
|
|
|
|
By:
|
/s/
John A. Roberts
|
|
Name:
|
John
A. Roberts
|
|
Title:
|
President
and Chief Executive Officer
|
Date:
May 1, 2018
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Aug 2023 to Aug 2024